NO330981B1 - Indol- eller benzimidazolderivater for modulering av IkB-kinase, fremgangsmate for fremstilling av disse, legemiddel og anvendelse av forbindelsene - Google Patents

Indol- eller benzimidazolderivater for modulering av IkB-kinase, fremgangsmate for fremstilling av disse, legemiddel og anvendelse av forbindelsene

Info

Publication number: NO330981B1
Authority: NO; Norway
Prior art keywords: compounds; indole; modulating; drug; preparation
Prior art date: 2002-08-17

Application number

NO20051337A

Other languages

English (en)

Norwegian (no)

Other versions

NO20051337L (no

Inventor

Gerhard Jaehne

Olaf Ritzeler

Original Assignee

Sanofi Aventis Deutschland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-17

Filing date

2005-03-15

Publication date

2011-08-29

2005-03-15 Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland

2005-05-03 Publication of NO20051337L publication Critical patent/NO20051337L/no

2011-08-29 Publication of NO330981B1 publication Critical patent/NO330981B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Tropical Medicine & Parasitology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
AIDS & HIV (AREA)

NO20051337A 2002-08-17 2005-03-15 Indol- eller benzimidazolderivater for modulering av IkB-kinase, fremgangsmate for fremstilling av disse, legemiddel og anvendelse av forbindelsene NO330981B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10237722A DE10237722A1 (de)	2002-08-17	2002-08-17	Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
PCT/EP2003/008629 WO2004022553A1 (de)	2002-08-17	2003-08-05	INDOL-ODER BENZIMIDAZOLDERIVATE ZUR MODULATION DER IλB-KINASE

Publications (2)

Publication Number	Publication Date
NO20051337L NO20051337L (no)	2005-05-03
NO330981B1 true NO330981B1 (no)	2011-08-29

Family

ID=31968974

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20051337A NO330981B1 (no)	2002-08-17	2005-03-15	Indol- eller benzimidazolderivater for modulering av IkB-kinase, fremgangsmate for fremstilling av disse, legemiddel og anvendelse av forbindelsene

Country Status (42)

Country	Link
US (2)	US7285560B2 (es)
EP (2)	EP1530568B1 (es)
JP (1)	JP4504812B2 (es)
KR (1)	KR101162046B1 (es)
CN (1)	CN1314683C (es)
AR (1)	AR040975A1 (es)
AT (2)	ATE493402T1 (es)
AU (1)	AU2003263196B2 (es)
BR (1)	BR0313562A (es)
CA (1)	CA2498559C (es)
CO (1)	CO5690586A2 (es)
CR (1)	CR7668A (es)
CY (2)	CY1111692T1 (es)
DE (2)	DE10237722A1 (es)
DK (2)	DK2233483T3 (es)
EC (1)	ECSP055612A (es)
ES (2)	ES2387954T3 (es)
HN (1)	HN2003000249A (es)
HR (1)	HRP20050042B1 (es)
IL (1)	IL166785A0 (es)
JO (1)	JO2764B1 (es)
MA (1)	MA27382A1 (es)
ME (1)	MEP60608A (es)
MX (1)	MXPA05001314A (es)
MY (1)	MY140074A (es)
NO (1)	NO330981B1 (es)
NZ (1)	NZ538296A (es)
OA (1)	OA12908A (es)
PA (1)	PA8580501A1 (es)
PE (1)	PE20040893A1 (es)
PL (1)	PL374229A1 (es)
PT (2)	PT1530568E (es)
RS (1)	RS51902B (es)
RU (1)	RU2318820C2 (es)
SI (2)	SI2233483T1 (es)
SV (1)	SV2004001599A (es)
TN (1)	TNSN05045A1 (es)
TW (1)	TWI290552B (es)
UA (1)	UA78591C2 (es)
UY (1)	UY27941A1 (es)
WO (1)	WO2004022553A1 (es)
ZA (1)	ZA200500322B (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19951360A1 (de) *	1999-10-26	2001-05-03	Aventis Pharma Gmbh	Substituierte Indole
DE10237723A1 (de) *	2002-08-17	2004-07-08	Aventis Pharma Deutschland Gmbh	Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
DE10237722A1 (de) *	2002-08-17	2004-08-19	Aventis Pharma Deutschland Gmbh	Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
AU2004205642C1 (en)	2003-01-14	2012-01-12	Arena Pharmaceuticals, Inc.	1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
AR045047A1 (es) *	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
JP2007537266A (ja) *	2004-05-12	2007-12-20	アベンティス・ファーマスーティカルズ・インコーポレイテツド	ＩκＢキナーゼ阻害剤として実質的に純粋な２−｛［２−（２−メチルアミノ−ピリミジン−４−イル）−１Ｈ−インドール−５−カルボニル］−アミノ｝−３−（フェニルピリジン−２−イル−アミノ）−プロピオン酸
TW200616967A (en)	2004-06-24	2006-06-01	Smithkline Beecham Corp	Novel indazole carboxamides and their use
DE102004033406A1 (de) *	2004-07-10	2006-02-16	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten
TW200626142A (en)	2004-09-21	2006-08-01	Glaxo Group Ltd	Chemical compounds
DOP2006000010A (es) *	2005-01-10	2006-07-31	Arena Pharm Inc	Procedimiento para preparar eteres aromáticos
WO2006076318A1 (en) *	2005-01-12	2006-07-20	Aventis Pharmaceuticals Inc.	Monopotassium salt of an ikb kinase inhibitor
US20070142417A1 (en) *	2005-05-11	2007-06-21	Aventis Pharmaceuticals Inc	Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor
DE102005025225A1 (de)	2005-06-01	2006-12-07	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
EA014083B1 (ru)	2005-06-30	2010-08-30	Смитклайн Бичам Корпорейшн	Новые производные индолкарбоксамида, содержащая их фармацевтическая композиция и способ лечения
US8063071B2 (en)	2007-10-31	2011-11-22	GlaxoSmithKline, LLC	Chemical compounds
US7855289B2 (en) *	2005-08-04	2010-12-21	Sirtris Pharmaceuticals, Inc.	Sirtuin modulating compounds
US8088928B2 (en) *	2005-08-04	2012-01-03	Sirtris Pharmaceuticals, Inc.	Sirtuin modulating compounds
US8093401B2 (en) *	2005-08-04	2012-01-10	Sirtris Pharmaceuticals, Inc.	Sirtuin modulating compounds
ES2431050T3 (es)	2005-08-04	2013-11-22	Sirtris Pharmaceuticals, Inc.	Benzotiazoles y tiazolopiridinas como moduladores de la sirtuína
EA200800755A1 (ru)	2005-09-07	2008-10-30	Лаборатуар Сероно С.А.	Ikk ингибиторы, предназначенные для лечения эндометриоза
JP2009001495A (ja) *	2005-10-13	2009-01-08	Taisho Pharmaceutical Co Ltd	２−アリール−ベンゾイミダゾール−５−カルボキサミド誘導体
AU2007283113A1 (en)	2006-08-08	2008-02-14	Sanofi-Aventis	Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
AR065804A1 (es)	2007-03-23	2009-07-01	Smithkline Beecham Corp	Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
TW200916472A (en) *	2007-06-20	2009-04-16	Sirtris Pharmaceuticals Inc	Sirtuin modulating compounds
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
BRPI0815154B1 (pt) *	2007-08-17	2024-01-30	Lg Chem, Ltd	Compostos de indol, composição, e, método de preparação da mesma
EP2215066A1 (en) *	2007-11-01	2010-08-11	Sirtris Pharmaceuticals, Inc.	Amide derivatives as sirtuin modulators
US20110009381A1 (en) *	2007-11-08	2011-01-13	Sirtis Pharmaceuticals, Inc.	Solubilized thiazolopyridines
EP2310372B1 (en)	2008-07-09	2012-05-23	Sanofi	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010071853A1 (en)	2008-12-19	2010-06-24	Sirtris Pharmaceuticals, Inc.	Thiazolopyridine sirtuin modulating compounds
SG174146A1 (en) *	2009-02-27	2011-10-28	Enanta Pharm Inc	Hepatitis c virus inhibitors
EP2406249A1 (en)	2009-03-10	2012-01-18	Glaxo Group Limited	Indole derivatives as ikk2 inhibitors
JP2013503135A (ja)	2009-08-26	2013-01-31	サノフイ	新規な結晶性複素芳香族フルオログリコシド水和物、その化合物を含んでなる医薬及びその使用
CA2786994C (en)	2010-01-27	2018-01-16	Arena Pharmaceuticals, Inc.	Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102858764B (zh)	2010-04-27	2014-08-20	和记黄埔医药（上海）有限公司	嘧啶基吲哚化合物
WO2011157827A1 (de)	2010-06-18	2011-12-22	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
PE20131326A1 (es)	2010-08-12	2013-11-12	Sanofi Sa	Procedimiento para preparar formas enantiomericas de derivados de acido 2,3-diaminopropionico
CA2812061A1 (en)	2010-09-22	2012-03-29	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
TW201242962A (en) *	2010-12-01	2012-11-01	Sumitomo Chemical Co	Pyrimidine compound and use for pest control thereof
WO2012120055A1 (de)	2011-03-08	2012-09-13	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120057A1 (de)	2011-03-08	2012-09-13	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en)	2011-03-08	2014-09-09	Sanofi	Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en)	2011-03-08	2014-09-09	Sanofi	Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8809324B2 (en)	2011-03-08	2014-08-19	Sanofi	Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683700B1 (de)	2011-03-08	2015-02-18	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683701B1 (de)	2011-03-08	2014-12-24	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
LT3333161T (lt)	2011-07-27	2020-05-11	Astrazeneca Ab	2-(2,4,5-pakeistieji-anilino)pirimidino dariniai kaip egfr moduliatoriai, naudingi vėžio gydymui
ME02908B (me) *	2011-08-25	2018-10-20	Medicines For Malaria Venture Mmv	Supstituisani 2-alkil-1-okso-n-fenil-3-heteroaril-1,2,3,4-tetrahidroizohinolin-4-karboksamidi za antimalarijske terapije
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013083553A1 (en) *	2011-12-06	2013-06-13	Sanofi	Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
EA202092034A3 (ru) *	2012-01-27	2021-02-26	Астразенека Аб	Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака
KR101493877B1 (ko)	2013-03-29	2015-02-16	농업회사법인 주식회사 생명의나무	스피나스테롤 당 유도체를 포함하는 골 질환 예방 또는 치료용 약학 조성물
EP3184095A1 (en)	2013-05-23	2017-06-28	IP Gesellschaft für Management mbH	Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
EP2905282A1 (en) *	2014-02-05	2015-08-12	AXXAM S.p.A.	Substituted thiazole or oxazole as P2X7 receptor antagonists
AU2015283052B2 (en) *	2014-07-03	2020-01-02	Sanofi	2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid ((s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl)-amide for use in the treatment of pain associated to osteoarthritis
MX386419B (es)	2015-01-06	2025-03-18	Arena Pharm Inc	Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
MA42807A (fr)	2015-06-22	2018-07-25	Arena Pharm Inc	Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
EP3290416A1 (en) *	2016-08-31	2018-03-07	AXXAM S.p.A.	Substituted n-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and n-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives and their use as p2x7 receptor antagonist
CN106588803A (zh) *	2016-11-16	2017-04-26	西南科技大学	一种制备5‑乙酰基异噁唑的新方法
CN108299302A (zh) *	2017-01-11	2018-07-20	西南科技大学	一种制备3-乙酰基吡唑的新方法
KR20190116416A (ko)	2017-02-16	2019-10-14	아레나 파마슈티칼스, 인크.	원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
KR102859841B1 (ko)	2018-06-06	2025-09-12	아레나 파마슈티칼스, 인크.	S1p1 수용체와 관련된 병태의 치료 방법
US12465608B2 (en)	2019-03-29	2025-11-11	Astrazeneca Ab	Osimertinib for use in the treatment of non-small cell lung cancer
EP4097084A4 (en) *	2020-01-30	2024-05-22	Anima Biotech Inc.	COLLAGEN-1 TRANSLATION INHIBITORS AND METHODS OF USE
CN115974849B (zh) *	2022-12-28	2024-06-21	中国药科大学	一种吲哚氧乙酰胺类衍生物、包含其的药物组合物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT97888B (pt) *	1990-06-07	1998-12-31	Zeneca Ltd	Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem
EP0664792B1 (en)	1992-10-14	2000-01-05	Merck & Co. Inc.	Fibrinogen receptor antagonists
GB9225141D0 (en)	1992-12-01	1993-01-20	Smithkline Beecham Corp	Chemical compounds
IT1275433B (it) *	1995-05-19	1997-08-07	Smithkline Beecham Farma	Derivati di diarildiammine
FR2763337B1 (fr) *	1997-05-13	1999-08-20	Sanofi Sa	Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant
DE50010931D1 (de)	1999-06-23	2005-09-15	Aventis Pharma Gmbh	Substituierte benzimidazole
DE19951360A1 (de) *	1999-10-26	2001-05-03	Aventis Pharma Gmbh	Substituierte Indole
JP2004529088A (ja)	2001-02-01	2004-09-24	ブリストル−マイヤーズ　スクイブ　カンパニー	ＩｋＢキナーゼ（ＩＫＫ）のインヒビターを用いる炎症性および免疫疾患の処置法
DE10237723A1 (de) *	2002-08-17	2004-07-08	Aventis Pharma Deutschland Gmbh	Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
US7462638B2 (en) *	2002-08-17	2008-12-09	Sanofi-Aventis Deutschland Gmbh	Use of IκB-kinase inhibitors in pain therapy
DE10237722A1 (de) *	2002-08-17	2004-08-19	Aventis Pharma Deutschland Gmbh	Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US7046741B2 (en) *	2004-04-16	2006-05-16	Data Flow Technologies, Inc.	Single and multiple sinewave modulation and demodulation techniques, apparatus, and communications systems

2002
- 2002-08-17 DE DE10237722A patent/DE10237722A1/de not_active Withdrawn
2003
- 2003-05-08 UA UAA200502387A patent/UA78591C2/uk unknown
- 2003-07-23 JO JO200387A patent/JO2764B1/en active
- 2003-08-05 PL PL03374229A patent/PL374229A1/xx unknown
- 2003-08-05 EP EP03793685A patent/EP1530568B1/de not_active Expired - Lifetime
- 2003-08-05 OA OA1200500047A patent/OA12908A/en unknown
- 2003-08-05 AT AT03793685T patent/ATE493402T1/de active
- 2003-08-05 MX MXPA05001314A patent/MXPA05001314A/es active IP Right Grant
- 2003-08-05 ES ES10163200T patent/ES2387954T3/es not_active Expired - Lifetime
- 2003-08-05 PT PT03793685T patent/PT1530568E/pt unknown
- 2003-08-05 EP EP10163200A patent/EP2233483B1/de not_active Expired - Lifetime
- 2003-08-05 HR HRP20050042AA patent/HRP20050042B1/hr not_active IP Right Cessation
- 2003-08-05 PE PE2003000772A patent/PE20040893A1/es not_active Application Discontinuation
- 2003-08-05 CN CNB038195437A patent/CN1314683C/zh not_active Expired - Fee Related
- 2003-08-05 BR BRPI0313562-4A patent/BR0313562A/pt not_active Application Discontinuation
- 2003-08-05 JP JP2004533319A patent/JP4504812B2/ja not_active Expired - Fee Related
- 2003-08-05 RS YU20050104A patent/RS51902B/sr unknown
- 2003-08-05 WO PCT/EP2003/008629 patent/WO2004022553A1/de not_active Ceased
- 2003-08-05 PT PT10163200T patent/PT2233483E/pt unknown
- 2003-08-05 SI SI200332173T patent/SI2233483T1/sl unknown
- 2003-08-05 DK DK10163200.8T patent/DK2233483T3/da active
- 2003-08-05 AT AT10163200T patent/ATE557018T1/de active
- 2003-08-05 DK DK03793685.3T patent/DK1530568T3/da active
- 2003-08-05 AU AU2003263196A patent/AU2003263196B2/en not_active Ceased
- 2003-08-05 SI SI200331971T patent/SI1530568T1/sl unknown
- 2003-08-05 NZ NZ538296A patent/NZ538296A/en not_active IP Right Cessation
- 2003-08-05 CA CA2498559A patent/CA2498559C/en not_active Expired - Fee Related
- 2003-08-05 RU RU2005107418/04A patent/RU2318820C2/ru not_active IP Right Cessation
- 2003-08-05 ME MEP-606/08A patent/MEP60608A/xx unknown
- 2003-08-05 ES ES03793685T patent/ES2358795T3/es not_active Expired - Lifetime
- 2003-08-05 DE DE50313372T patent/DE50313372D1/de not_active Expired - Lifetime
- 2003-08-05 KR KR1020057002707A patent/KR101162046B1/ko not_active Expired - Fee Related
- 2003-08-12 PA PA20038580501A patent/PA8580501A1/es unknown
- 2003-08-14 AR ARP030102946A patent/AR040975A1/es not_active Application Discontinuation
- 2003-08-14 TW TW092122309A patent/TWI290552B/zh not_active IP Right Cessation
- 2003-08-15 HN HN2003000249A patent/HN2003000249A/es unknown
- 2003-08-15 SV SV2003001599A patent/SV2004001599A/es unknown
- 2003-08-15 MY MYPI20033115A patent/MY140074A/en unknown
- 2003-08-15 UY UY27941A patent/UY27941A1/es unknown
- 2003-08-18 US US10/642,970 patent/US7285560B2/en not_active Expired - Lifetime
2005
- 2005-01-13 ZA ZA200500322A patent/ZA200500322B/en unknown
- 2005-01-28 CR CR7668A patent/CR7668A/es unknown
- 2005-02-09 IL IL16678505A patent/IL166785A0/xx not_active IP Right Cessation
- 2005-02-15 MA MA28106A patent/MA27382A1/fr unknown
- 2005-02-15 CO CO05013335A patent/CO5690586A2/es active IP Right Grant
- 2005-02-16 TN TNP2005000045A patent/TNSN05045A1/en unknown
- 2005-02-17 EC EC2005005612A patent/ECSP055612A/es unknown
- 2005-03-15 NO NO20051337A patent/NO330981B1/no not_active IP Right Cessation
2007
- 2007-06-06 US US11/758,978 patent/US8778955B2/en not_active Expired - Fee Related
2011
- 2011-03-02 CY CY20111100246T patent/CY1111692T1/el unknown
2012
- 2012-07-24 CY CY20121100658T patent/CY1112991T1/el unknown

Also Published As

Publication number	Publication date
EP1530568A1 (de)	2005-05-18
CN1314683C (zh)	2007-05-09
HRP20050042A2 (en)	2006-03-31
PL374229A1 (en)	2005-10-03
TW200418832A (en)	2004-10-01
DK1530568T3 (da)	2011-04-18
TNSN05045A1 (en)	2007-05-14
RS51902B (sr)	2012-02-29
SI2233483T1 (sl)	2012-08-31
CY1112991T1 (el)	2016-04-13
RU2318820C2 (ru)	2008-03-10
MY140074A (en)	2009-11-30
DE10237722A1 (de)	2004-08-19
BR0313562A (pt)	2006-06-13
JP4504812B2 (ja)	2010-07-14
JO2764B1 (en)	2014-03-15
CY1111692T1 (el)	2015-10-07
PA8580501A1 (es)	2004-04-23
ATE557018T1 (de)	2012-05-15
NZ538296A (en)	2007-03-30
DK2233483T3 (da)	2012-08-20
OA12908A (en)	2006-10-13
SI1530568T1 (sl)	2011-05-31
ES2387954T3 (es)	2012-10-04
ZA200500322B (en)	2006-07-26
PT1530568E (pt)	2011-02-23
UA78591C2 (en)	2007-04-10
AU2003263196B2 (en)	2009-01-22
HN2003000249A (es)	2008-08-06
RU2005107418A (ru)	2005-08-27
EP2233483B1 (de)	2012-05-09
TWI290552B (en)	2007-12-01
US20070244139A1 (en)	2007-10-18
RS20050104A (sr)	2007-06-04
CN1675196A (zh)	2005-09-28
WO2004022553A1 (de)	2004-03-18
AU2003263196A1 (en)	2004-03-29
MA27382A1 (fr)	2005-06-01
IL166785A0 (en)	2006-01-15
KR20050058338A (ko)	2005-06-16
CR7668A (es)	2009-03-11
HK1079509A1 (en)	2006-04-07
SV2004001599A (es)	2004-02-26
UY27941A1 (es)	2004-03-31
PT2233483E (pt)	2012-07-20
EP2233483A1 (de)	2010-09-29
CA2498559C (en)	2012-01-24
US7285560B2 (en)	2007-10-23
JP2005539054A (ja)	2005-12-22
EP1530568B1 (de)	2010-12-29
US8778955B2 (en)	2014-07-15
MXPA05001314A (es)	2005-04-28
ECSP055612A (es)	2005-04-18
PE20040893A1 (es)	2004-12-21
ATE493402T1 (de)	2011-01-15
MEP60608A (en)	2011-05-10
ES2358795T3 (es)	2011-05-13
NO20051337L (no)	2005-05-03
DE50313372D1 (de)	2011-02-10
KR101162046B1 (ko)	2012-07-04
CA2498559A1 (en)	2004-03-18
HRP20050042B1 (hr)	2013-09-30
US20050197353A1 (en)	2005-09-08
AR040975A1 (es)	2005-04-27
CO5690586A2 (es)	2006-10-31

Publication	Publication Date	Title
NO330981B1 (no)	2011-08-29	Indol- eller benzimidazolderivater for modulering av IkB-kinase, fremgangsmate for fremstilling av disse, legemiddel og anvendelse av forbindelsene
MY139302A (en)	2009-09-30	Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
NO20061506L (no)	2006-06-02	Heterocykliske inhibitorer av MEK og fremgangsmater for anvendelse derav
NO20050828L (no)	2005-04-05	lndol-3-svovelderivater
IS8132A (is)	2005-11-18	Pýrósóló-kínasólín afleiður, aðferð við framleiðslu þeirra og notkun sem kínasa hindrar
NO20055421L (no)	2005-12-20	Kinolinderivater som fosfodiestrase-inhibitorer
BRPI0413427A (pt)	2006-10-10	derivados de piridilpirrol ativos como inibidores da cinase
DE60319158D1 (de)	2008-03-27	Pyrazoloisoquinolinenderivaten als kinase inhibitoren
ATE408601T1 (de)	2008-10-15	Fredericamycin-derivate
MXPA06000302A (es)	2006-04-18	Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
NO20051339L (no)	2005-05-03	Anvendelse av lkB-kinaseinbibitorer ved behandling av smerte.
TW200610527A (en)	2006-04-01	Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
BRPI0413438A (pt)	2006-10-17	derivados de pirimidilpirrol ativos como inibidores de cinase
DE60206911D1 (de)	2005-12-01	Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
NO20056030L (no)	2006-02-15	Nye pyridopyraziner og anvendelse derav som kinaseinhibitorer
ATE341545T1 (de)	2006-10-15	Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
NO20043792L (no)	2005-01-04	New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
IL166057A0 (en)	2006-01-15	Urea-substituted and urethane-substituted acylureas methods for the production thereof and their useas medicaments
NO20061821L (no)	2006-06-22	Amidometylsubstituerte 1-(karboksyalkyl)-syklopentylkarbonylaminobenzazepin-N-eddiksyrederivater, fremgangsmate og mellomprodukter for deres fremstilling, og medikamenter som inneholder disse forbindelsene
ATE373658T1 (de)	2007-10-15	Pyrazoloisoquinolinenderivaten zur inhibierung von nfkappab-induzierende kinase
NO20081818L (no)	2008-06-19	Arylsulfonylkromaner som 5-HT6-inhibitorer - indolylmaleimidderivater som protein kinaseinhibitorer
ATE412416T1 (de)	2008-11-15	Indolin-2-one-pyridin-derivate, herstellung und therapeutische verwendung dafür
SE0303075D0 (sv)	2003-11-19	4-substituted imidazoles
NO20065783L (no)	2006-12-13	Pyridin-4-yl-etyl-imidazoler og pyrazoler som MGLU5 reseptor antagonister
SE0303076D0 (sv)	2003-11-19	5-substituted imidazoles

Legal Events

Date	Code	Title	Description
2016-03-29	MM1K	Lapsed by not paying the annual fees